Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

Opens in a new tab or window Geographic atrophy (GA ... and now we have a lot of evidence in terms of using OCT [optical coherence tomography] and getting much more information." ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...

The results were published in The Lancet in October 2023. About SYFOVRE ® (pegcetacoplan injection) SYFOVRE ® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA).